DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will join a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on May 19, 2026, at 9:00 a.m. ET in New York.
A live webcast and 90-day replay will be available on the company’s investor events webpage.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – DBVT
On the day this news was published, DBVT declined 2.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DBVT was up 3.19% pre-news while peers were mixed: OMER +1.93%, NGNE +2.87%, but CADL -1.91%, ANNX -3.02%, CAPR -0.19%, indicating stock-specific strength rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Q1 2026 earnings | Negative | -5.4% | Q1 2026 loss of $47.6M and higher R&D and SG&A spending. |
| Apr 02 | Share count update | Neutral | -3.3% | Report of total shares and voting rights as of March 31, 2026. |
| Mar 26 | Annual report filing | Neutral | -1.0% | Filing of 2025 Form 10-K and Universal Registration Document. |
| Mar 26 | FY 2025 earnings | Positive | -1.0% | Full-year 2025 update with positive VITESSE data and strong cash runway. |
| Mar 24 | Index inclusion | Positive | +3.7% | Inclusion in CAC Mid 60 and SBF 120 indices on March 23, 2026. |
Recent news and earnings often saw modest negative reactions, even around positive clinical and index-inclusion milestones, suggesting a cautious market stance toward DBVT updates.
Over the last few months, DBV Technologies reported Q1 2026 results with $229M cash and a net loss of $47.6M, alongside higher R&D and SG&A as it advances VIASKIN® Peanut Patch BLA submissions. Full-year 2025 results highlighted positive Phase 3 VITESSE topline data, financings totaling $386.2M, and cash runway into Q2 2027. The company also joined the CAC Mid 60 and SBF 120 indices. Against this backdrop, today’s conference appearance fits an ongoing investor-engagement and commercialization narrative.
Market Pulse Summary
This announcement details DBV Technologies’ participation in an investor conference, featuring a CEO fireside chat and a webcast replay available for 90 days. In recent months, the company has reported positive Phase 3 VITESSE data, strengthened its cash position to support operations into Q2 2027, and gained inclusion in the CAC Mid 60 and SBF 120 indices. Investors may focus on any incremental commentary around VIASKIN® Peanut Patch BLA submissions, commercialization plans, and ongoing pediatric trials.
AI-generated analysis. Not financial advice.
Châtillon, France, May 12, 2026
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq, which is being held May 19, 2026 in New York, NY. Mr. Tassé’s presentation is scheduled for Tuesday, May 19, at 9:00 am ET.
A live webcast of the fireside chat can be accessed here and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/
A replay will also be available on DBV Technologies’ website for 90 days after the event.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of the VIASKIN Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
